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Summary: We followed a cohort of 223 intravenous drug users (99 HIV- and 124 
HIV+) for up to 3.5 years, examining change in performance over time as a func-
tion of HIV status, disease severity, and neurological signs and symptoms. Analy-
ses were performed by applying generalized estimating equations (GEE) to regres-
sion analyses with repeated measures, and controlled for age, education, and 
length of substance use. None of the subjects had AIDS at baseline. There were 147 
men (85 HIV+ and 62 HIV-) and 76 women (39 HIV+ and 37 HIV-). Memory 
performance was worse in the HIV+ than HIV- women. In the men, performance 
on the memory, executive, language, and attention factors improved significantly 
over time, but this improvement was attenuated in the HIV+ men for the attention 
and orientation factors. In the HIV+ women, AIDS was associated with worsening 
performance on attention tests. The presence or onset of clinically significant neu-
rological findings was associated with poorer language and motor speed perfor-
mance. In the HIV+ men, memory performance was worse when the CD4 count 
fell below 200; it declined over time in men with AIDS but not in those without. 
A learning effect for language was attenuated in 1nen who developed AIDS. The 
presence or development of a clinically significant neurological sign was associated 
with poorer memory, executive, language, attention, and motor speed perfor-
mance. Our findings parallel those that we previously reported in a prospectively 
followed cohort of gay men. In combination, our studies of gay men and IDU 
cohorts suggest that (a) HIV can affect cognition early, even when the patient is 
medically asymptomatic; (b) cognitive difficulties worsen as the severity of HIV 
infection increases; and (c) the advent of clinically significant ncurologic signs is 
associated with progression to more severe cognitive deficits. Our data suggest that 
the neurological and neuropsychological changes arc both manifestations of the 
central effect of HIV on the CNS. Key Words: HIV-Cognition-Intravenous 
drug use-Prospective cohort studies. NNBN 9:83-90, 1996 
Intravenous drug users (IDU's) are the fastest grow-
ing portion of the HIV epidemic. Still, relatively little 
attention has been afforded to potential neuropsycho-
logical changes in this group, and prospective studies 
are rare. Studies of IDU's are more complex, in that 
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they must carefully control for potential covariates, 
including socioeconomic factors such as lower educa-
tion, medical features such as head injury, and drug 
use. However, studies of IDU's may be more likely 
to detect subtle neuropsyehological changes, because 
these individuals' lower education and socioeco-
nomic status might provide a lower threshold for ob-
serving the effects of the virus on the central nervous 
system. In addition, they allow the opportunity to 
evaluate the effects of alternate modes of HIV trans-
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nnss10n as well as the potential effects of HIV on 
women, another understudied group. 
Two studies found that HIV+ IDU's had more 
rapid decline of neuropsychological test performance 
than HIV- controls ( 1,2), but a third study (3) did not. 
We previously reported a cross-sectional analysis that 
demonstrated subtle differences between seronegative 
and seropositive IDU's performance on a neuropsy-
chological test battery (4). We also noted an interac-
tion between history of head injury and serostatus 
such that neuropsychological performance was sig-
nificantly worse in the HIV+ subjects reporting a his-
tory of head injury. We have now followed this cohort 
of IDU's for up to 3.5 years and describe change in 
performance over time as a function of HIV status, 
disease severity, and neurological signs and symp-
toms. Because of their particular salience in this 
group, we paid close attention to the potential effects 
of previous and current drug use, education, and head 
injury. In addition, systematic differences between the 
men and women in our cohort prompted us to ana-
lyze their data separately. 
We hypothesized that HIV's effect on cognitive 
function in IDU's would be similar to that already 
noted in gay men. In a prospective study of our gay 
men cohort, we found that neuropsychological test 
performance tended to improve over time, but that 
this improvement was attenuated or eliminated in the 
HIV+ group for some tests (5). In addition, lower CD4 
counts, more advanced disease stage, and the presence 
of neurological signs were each associated with poorer 
test performance and more marked decline over time. 
Observing a similar pattern of cognitive changes in the 
IDU's would provide additional evidence for the di-
rect effect of HIV on the CNS, in the form of interre-
lated cognitive and neurological changes. 
METHODS 
Subjects 
Two hundred and twenty-three IDU's (99 Hiv-
and 124 HIV+) were recruited in late 1988 through 
1989. These included 147 men (85 HIV+ and 62 
HIV-) and 76 women (39 HIV+ and 37 HIV-). The 
majority ( 170) were recruited from the Harlem Hos-
pital Infectious Disease Clinic, New Yark; 5 3 were re-
cruited from the St. Luke's Roosevelt Methadone 
Maintenance Clinic, New Yark. Inclusion and exclu-
sion criteria and screening procedures have been de-
scribed elsewhere ( 4,6). All subjects were volunteers 
and gave informed consent. All participants had used 
intravenous drugs at least 10 times since 1982. In the 
HIV+ subjects, 41 % used heroin in the 6 months be-
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fore their initial visit, 71 o/o used cocaine or crack, and 
50% used alcohol. For the same period, 43% of the 
HIV- subjects used heroin, 61 % cocaine or crack, and 
5 5 % alcohol. 
Assessments 
All subjects who entered the longitudinal phase 
were examined every 6 months for up to eight visits 
(3.5 years). At each visit, subjects received a standard-
ized medical examination for staging, and neurologi-
cal, neuropsychological, psychiatric, and psychosex-
ual assessments. These assessments have been de-
scribed previously (7,8); relevant assessments are 
summarized below. 
Medical Assessment 
Physicians performed physical examinations tar-
geted at HIV-related symptoms and signs. Subjects 
who met 1987 CDC criteria for AIDS (9) at baseline 
were not included in the study, with two exceptions. 
Because of the difficulty in distinguishing clinically 
between oral and esophageal candidiasis on routine 
physical exam, we did not exclude men with esopha-
geal candidiasis, which is, on its own, a criterion for 
AIDS. We also did not use the presence of cognitive 
impairment as an exclusion criterion because the pur-
pose of the study was to assess nervous system abnor-
malities in relatively medically asymptomatic indi-
viduals. Blood for CD4 counts was obtained at each 
visit. 
Following each study visit, HIV+ patients were clas-
sified into disease stages, based on previously de-
scribed criteria ( 10). For the present analyses we con-
sider three severity stages: asymptomatic or mildly 
symptomatic, signs and symptoms consistent with 
AIDS-related complex (ARC), and AIDS. 
Neurological Assessment 
All neurological examinations were performed by 
neurologists who were blind to the HIV status of the 
subjects. An overall measure of neurological disability 
was calculated for each subject, based on the Kurtzke 
Disability Status Scale for Multiple Sclerosis ( 11 ). The 
Kurtzke scale reflects both the number of areas of 
neurological dysfunction (i.e., pyramidal tract, cere-
bellar, brainstem, etc.) and the severity of impair-
ment. Derivation of the Kurtzke for use in HIV has 
been previously described (12). We subdivided sub-
jects into those with and without clinically significant 
neurological findings, using a score of three or above 
on the Kurtzke scale as the cut-off point. 
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Neuropsychologica/ Assessment 
The neuropsychological battery was also adminis-
tered blind to HIV status and included the following 
tests. 
The 10 orientation items from the Mini-Mental 
State Examination (13) were used to assess orienta-
tion to time and place. Attention was assessed with 
two types of cancellation tasks, one utilizing a shape 
and another a letter triad as targets ( 14 ), and the 
WAIS-R Digit Symbol subtest (15). Verbal fluency 
was assessed with the controlled oral word association 
test (60 s for each of the letters C, F, and L) (16) and 
animal naming (17). The Odd Man Out Test (18,19) 
was used to assess executive or "frontal lobe" func-
tion. The Trail Making Test was also administered as 
a test of speeded performance and, in part B, of rapid 
sequencing and set shifting (20). Motor speed and 
praxis was assessed with the Grooved Pegboard (21 ). 
A 12-item, six-trial selective reminding test assessed 
verbal memory (22). 
In our prospective study of gay men (12), we per-
formed a factor analysis of the neuropsychological test 
scores at the baseline visit and assessed stability of the 
factors at the follow-up visits. Then, using these factor 
analyses as a guide, we constructed six neuropsycho-
logical factor scores. To provide comparability to the 
studies of gay men, these factor scores were used in 
the current analyses. The factors were (a) memory: se-
lective reminding test total score; (b) motor speed: 
grooved pegboard, time to insert pegs with dominant 
hand; (c) executive: Odd Man Out total score and 
Trails B time; (d) language: number of words reported 
on animal naming and CFL; ( e) attention: Digit Sym-
bol Age Scaled score, shape and letter cancellation 
time; and (f) orientation: orientation score. Although 
the name of each factor reflects our view of the pri-
mary cognitive function tapped, certainly these fac-
tors reflect multiple processes. For example, the tests 
included in the attention factor also require psycho-
motor speed and scanning. 
To calculate summary scores for each patient, each 
component score was first transformed into a z score 
based on the mean and SD oftest scores of all subjects 
assessed at the baseline visit. The z scores were ad-
justed for direction (i.e., whether higher scores indi-
cate better or worse performance). Factor scores then 
were calculated as sums of the z scores for measures 
within each factor. The range of scores on the orienta-
tion test was severely restricted (i.e., few errors were 
made). For statistical purposes, performance on this 
factor was expressed as the number of errors. Thus, 
for orientation and motor speed (which is expressed 
as time to completion), higher scores represent poorer 
performance. 
Drug Use 
All subjects were systematically interviewed at each 
visit about their drug and alcohol usage. Use of all 
forms of heroin, all forms of cocaine, benzodiaze-
pines, hallucinogens, and phencyclidine was assessed. 
We created a composite variable to reflect the length 
of time subjects had used either heroin, cocaine, or 
alcohol. The number of years since first substance use 
was highly correlated with the age of the subjects, so 
the variable included both age and years of drug use. 
Based on median values, years of illicit drug nse were 
dichotomized into "long" (z 15 years) and "short" 
(> 15 years), and alcohol use was dichotomized into 
"long" (z20 years) and "short" ( <20 years). If either 
drug use or alcohol use was considered "long," the 
subject was considered to have a "long" history of 
substance abuse. Women's age was dichotomized at 
40 years and men's at 45 years. Because no subjects in 
the higher age groups had a short history of use, men 
and women were divided into three age/substance 
abuse groups reflecting younger individuals with 
short- and long-term use and older individuals with 
long-term use. In this way, the proportion of subjects' 
lives during which they used drugs or alcohol was cap-
tured. 
As another index of substance use, frequency of 
drug and alcohol use in the 6 months before each visit 
was dichotimized into "high" (weekly use or more) 
and "low" (monthly use or less). These data were 
available only for visits 2-7 and were therefore used 
only for supplemental analyses. 
Statistical Analysis 
Analyses of the longitudinal data were done by ap-
plying generalized estimating equations (GEE) to re-
gression analyses with repeated measures (23). This 
statistical method takes into account the multiple vis-
its per subject and the fact that the characteristics of a 
single individual over time are likely to be correlated 
with one another. The repeated measures for each 
subject (up to eight per variable) are treated as a clus-
ter. A second advantage of GEE is that it takes into 
account the status or changing value of each covariate 
at each visit. Tabled values for regression analyses in-
volving the factor scores are regression coefficients 
and their SE. All analyses controlled for age and edu-
cation by including them as covariates. 
The distributions of all factors except orientation 
were approximated by a normal distribution. As 
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noted above, scores for the orientation factor had an 
attenuated range and were converted to error scores; 
their distribution was approximated by a Poisson dis-
tribution. 
Data on recent (past 6 months) substance use was 
available only for visits 2-7. We assessed the potential 
influence of the frequency of recent substance use on 
neuropsychological factor scores by calculating 
models that included substance use and follow-up 
time, controlling for age and education. To best assess 
the influence of substance use, analyses were limited 
to the HIV- subjects. There were no significant sub-
stance use effects for any of the neuropsychological 
factors. Because including recent substance use in all 
analyses would require truncating the data set and 
based on the lack of current drug use effects in the 
HIV- subjects, we chose not to control for recent sub-
stance use in the analyses. 
Data analysis was divided into two series: the first 
included both HIV- and HIV+ subjects, whereas the 
second included only the HIV+ subjects. 
The initial series of analyses included both Hiv-
and HIV+ subjects, and examined test factor perfor-
mance over time as a function of serostatus. Because 
men and women differed significantly on several de-
mographic and clinical variables, their data were ana-
lyzed separately. The regression models provided esti-
mates of the association of neuropsychological factor 
scores with serostatus, follow-up time, and the in-
teraction of serostatus and time. A significant interac-
tion of HIV status and time would indicate differen-
tial rates of change in a factor score as a function of 
HIV status. All analyses controlled for age, education, 
and the composite drug use history variable. Because 
a history of head injury interacted with serostatus in 
our previously reported analysis of the data from the 
baseline visit, this interaction was investigated as well. 
If a specific component of the model was not signifi-
cant at the p,; 0.05 level, it was eliminated from the 
model. Thus, drug use or head injury effects are re-
ported only when they were significant. 
The second series of analyses were restricted to the 
HIV+ subjects, with the data for men and women 
again evaluated separately. Two groups ofregression 
analyses explored the contribution of disease severity, 
first as a function of CD4 count (stratified into three 
ranges: <200, 200-500, > 500), and then as a function 
of disease stage. A third group of analyses evaluated 
the relationship between neuropsychological perfor-
mance and clinically significant neurological findings 
(Kurtzke score: <3 versus ~3). The same analytic ap-
proach was taken as described above for the first series 
of analyses, with two exceptions. First, because the 
substance abuse history variable correlated strongly 
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with age, it was not included. Second, if interactions 
with follow-up time were not significant, they were 
also trimmed from the model. Thus, the reported re-
sults reflect only the components of the model that 
were significant and were retained. 
RESULTS 
Demographics 
CD4 count was significantly lower (p < 0.0001) and 
the Kurtzke score significantly higher (p < 0.01) in 
HIV-positive subjects compared with HIV-negative 
subjects (Table 1). Reported substance use did not sig-
nificantly differ by HIV status at baseline. 
Men were significantly older (p < 0.05) but had sig-
nificantly lower Kurtzke scores (p < 0.01) than 
women, indicating that men had less neurological im-
pairment at baseline. Men were more likely to be 
long-term abusers of drugs and alcohol (p < 0.05) and 
to report head injury with loss of consciousness (p 
< 0.05). 
None of the subjects met our criteria for AIDS at 
baseline. A similar proportion of men and women 
were asymptomatic/mildly symptomatic, or met cri-
teria for AIDS related complex (ARC). The propor-
tion of HIV+ men and women with CD4 of ,;200 was 
also similar. 
Two men and four women seroconverted during 
the study. In the HIV+ subjects, there were 32 deaths 
(22 men, lO women), and 33 subjects (24 men, nine 
women) were lost to follow-up (did not complete all 
eight visits, but did not die). Among HIV-negative 
subjects, there were four deaths (all men) and 35 sub-
jects lost to follow-up (19 men, 16 women). One HlV-
negative woman seroconverted during follow-up and 
subsequently died; she was counted among the HIV-
positive deaths. Two of the HIV-positive subjects died 
soon after completing their eighth visit and were con-
sidered among the deaths. Not all deaths in the HIY' 
subjects were directly HIV-related. At visit 8, there 
were 66 HIV+ subjects (41 men, 25 women) and 55 
HIV- subjects (38 men, 17 women). 
HIV+ Versus HIV- Women 
Older women with long-term drug use performed 
more poorly than younger women with short-term 
use on the memory, executive, attention, and motor 
speed factors (Table 2). Controlling for education and 
the composite age/drug use variable, performance on 
the memory, executive, and attention factors im-
proved over time and HIV+ women performed more 
NEUROPSYCIIOLOGY IN DRUG USERS WITH lIIV 87 






CD4,,; 200 (%) 
Kurtzke score 
Ku1izke 2: 3 (%) 
Stage at baseline(%) 
Asym/mild sym 
ARC 
ETOH 2: 20 years (%) 
Drug use 2::: 15 years (%) 
Any long-term drug use(%) 





















































a Values in parentheses are SD for means and actual numbers for percentages. 
poorly on the memory factor. There was no difference 
detected in the rate of change over time in any score. 
There was a significant serostatus X head injury in-
teraction for the orientation factor, such that perfor-
mance was significantly worse in the HIV+ (but not 
HIV-) subjects reporting a history of head injury with 
loss of consciousness. 
HIV+ Versus HIV- Men 
Older men with long-term drug use performed 
more poorly than younger short-term users on the 
memory attention and motor speed factors (Table 3). 
Adjusting for education and age/drug use, perfor-
mance on the memory, executive, language, and at-
tention factors improved significantly over time. The 
time X serostatus interaction term for these four fac-
tors was negative, suggesting that improvement was 
attenuated in the HIV+ men. This attenuation was sig-
nificant for the attention factor and is illustrated in the 
TABLE 2. For women, regression coefficients (SE) 
assessing the association o.f each.factor score with 
serostatus,.fo!low-up time, and their interaction a 
Factor Serostatus Time Serostatus X Time 
Memory -0.44 (0.20)" 0.11 (0.05)' 0.06 (0.07) 
Executive -0.49 (0.36) 0.20 (0.07)" -0.06 (0.13) 
Language -0.19 (0.35) 0.11 (0.09) 0.15(0.13) 
Attention -0.87 (0.53) 0.25 (0.12)" 0.18(0.18) 
Motor speed 0.15 (0.29) -0.07 (0.06) 0.05 (0.09) 
Orientation 0.28 (0.35) 0.18 (0.10) -0.26 (0.17) 
a Analyses control for age and education. Note that for motor 
speed and orientation, higher scores denote poorer pcrfonnance, so 
the directionality of the regression coefficients is reversed, 
"p<0.05. 
figure (Fig. l ). Time trends can be estimated sepa-
rately for HIV- and Hrv+ men hy summing the re-
gression coefficients for the time and interaction 
terms. Using this approach, HIV- men had learning 
effects for the memory, executive, language, and at-
tention factors, but Hrv+ men had a learning effect 
only for the executive and language factors. 
The error score for orientation was unchanged over 
time in the HIV- men, but increased in the HIV+ 
men, yielding a significant time X serostatus interac-
tion. 
HIV+ Women 
In the HIV+ wo1nen, no association between a low 
CD4 count and neuropsychological test performance 
was detected. AIDS was associated with worsening 
performance on the attention factor (Table 4 ). The 
presence or onset of clinically significant neurological 
findings was associated with poorer performance on 
the language and motor speed factors (p < 0.05 for 
both), and weakly associated with the memory (p 
= 0.07) and attention (p = 0.06) factors (Table 4). 
HIV+ Men 
In the HIV+ men, 1nemory performance was worse 
in subjects when the CD4 count fell below 200 (Table 
5). There was also a significant AIDS X time interac-
tion for memory and language: memory performance 
declined over time in the men with AIDS but not in 
those without, and the learning effect for language was 
attenuated in men who developed AIDS (Table 5). 
The presence or development of a clinically signifi-
cant neurological sign was associated with poorer per-
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TABLE 3. For men, regression coefficients (SE) 
assessing the association of each JG,ctor score with 
serostatus,follow-up time, and their interaction a 
Factor Serostatus Time Serostatus X Time 
Memory -0.16 (0.15) 0.11 (0.04)' -0.07 (0.06) 
Executive -0.06 (0.25)' 0.28 (0.07)' -0.06 (0.09) 
Language -0.36 (0.26) 0.19 (0.07)' -0.04 (0.09) 
Attention 0.25 (0.43) 0.55 (0.12)" -0.51 (0.17)" 
Motor speed 0.13(0.14) -0.03 (0.04) -0.02 (0.05) 
Orientation -0.19 (0.28) -0.10 (0.10) 0.30(0.12)" 
"Analyses control for age and education. Note that for motor 
speed and orientation higher scores denote poorer performance, so 
the directionality of the regression coefficients is reversed. 
b p < 0.05. 
formance on the memory, executive, language, atten-
tion, and motor speed factors (Table 5). 
DISCUSSION 
The present findings confirm and extend previous 
prospective observations of cognitive change in HIV 
among well-educated, high-socioeconomic gay and 
bisexual men, and our initial cross-sectional evalua-
tions of our !DU cohort. Because none of our cohort 
had AIDS at their initial visit, any effects of HIV on 
test performance would be expected to be quite subtle. 
In addition, the ability to observe HIV-related cogni-
tive changes in the IOU cohort is complicated by vari-
ability in socioeconomic background, more pro-
nounced medical problems, and drug usage. Still, we 
reported small but statistically significant differences 
between the performance of HIV- and HIV+ subjects 
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ministered every 6 months, subjects would be ex-
pected to become quite familiar with the test materi-
als. In fact, a striking feature of the present prospective 
analyses is the general trend for improved perfor-
mance over time on all the neuropsychological test 
factors considered. The potential effects of HIV on 
performance therefore must be judged against a back-
ground of improving scores. We found that HIV was 
associated with poorer performance on some tests and 
a blunting or reversal of a learning effect on others. 
In addition, poorer neuropsychological performance 
was noted as a function of the presence or develop-
ment of more advanced disease or of clinically sig-
nificant neurologic findings. Test findings parallel 
those that we previously reported in a prospectively 
followed cohort of gay men ( 12), and suggest that the 
effect of HIV on the central nervous system is similar 
in gay men and IDU's. 
/. 
FlG.1. Change In attention factor scores for 
HIV- and HIV+ subjects over each study visit 
The regression lines are derived from the GEE 
model. The squares indicate the mean ob-
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TABLE 5. In HIV+ men only, regression coefficients 







CD4 Stage X time Kurtzke score 
-0,35 (0,16)' -0.59 (0.25)b -0.32(0,12f' 
-0.47(0,17)" 
-0.61 (0.2 l)b -0.55 (0.20)" 
-0.90 (0.34)b 
0.27 (0.12)" 
a Variables include CD4 count ( <200 vs. >500), disease stage (no 
AIDS vs. AIDS), and the presence or absence of clinically significant 
neurological findings (Kurtzke score stratified at 3). All analyses 
control for age and education and follow-up time (when they are 
significant). The interaction coefficients are included when they 
were significant. Note that for motor speed higher scores denote 
poorer performance, so the directionality of the regression coeffi-
cients is reversed. 
b p < 0.05. 
We analyzed women's and men's data separately 
because they differed at baseline on several demo-
graphic and disease severity variables and because our 
data suggested that their drug use patterns differed 
during follow-up. The power of the analyses of the 
women's data was comparatively reduced because of 
this group's smaller size. Thus, for example, the rela-
tion between CD4 count and memory performance 
noted in the men could not be detected in the women. 
Still, the pattern of results was quite similar in the men 
and women. 
Few studies have prospectively investigated neuro-
psychological changes in HIV+ IDU's. In a follow-up 
study of 128 methadone-maintained IDU's, neuro-
psychological performance declined more rapidly in 
the HIV' than the HIV- subjects ( 1 ). In another study 
of220 IDU's (2) (27 HIV-, 193 HIV+), symptomatic 
patients (in CDC stage IV) were impaired on Trails B, 
two-choice decision time, delayed recall of the Wechs-
ler Logical Memory Test, and most components of 
the Auditory Verbal Learning Test. A total of 101 pa-
tients was retested at a mean of 16 months after their 
initial assessment. Performance on Trails A and B, 
Block Design, and delayed recall of the Wechsler Log-
ical Memory Test deteriorated more for patients at or 
progressing within CDC stage IV, than performance 
of patients at stage III. Performance on all tests of 
memory function declined independent of clinical 
staging. The MACS study also evaluated a group of 
102 AIDS-free, mv+ IDU's along with 49 HIV- con-
trols (3). At baseline, there were no significant differ-
ences in test performance attributable to HIV. There 
were also no differences in performance by serostatus 
group at either 6- or 12-month follow-up visits. Im-
provement in performance secondary to practice 
effects was comparable in both serostatus groups. 
Thus, two other studies, but not the MACS group, 
have noted cognitive changes that progress over time 
associated with HIV in IDU's. Bornstein (24) reviews 
some potential explanations for the discrepancies be-
tween the MACS group's and others' findings. 
Analysis of data from an !DU population is more 
complex than that from gay men cohorts for many 
reasons (25). This population has more variable SES, 
educational background, and medical history. Over-
all, baseline performance on all tests was significantly 
lower than that observed in a gay men cohort. A nota-
ble concern is the possible effect of drug use on neuro-
psychological test performance. Evaluation of this is-
sue is complicated by difficulties in documenting cur-
rent and past drug use. In addition, the potential effect 
of drug use on test performance has not been exten-
sively investigated. The literature on neuropsycholog-
ical performance in intravenous drug users is sparse. 
However, it does suggest that some drugs, particularly 
opiates, can affect performance on neuropsychologi-
cal testing (26). The issue is complicated by the varia-
tions in the pattern of drug use. Logically, factors such 
as duration of drug abuse, the actual drug/s used, or 
whether the patient is currently intoxicated or not 
might have direct effects on neuropsychological test 
performance. We addressed these issues in several 
ways. First, patients were not tested when they were 
acutely intoxicated. Second, we evaluated the relation 
of measures of recent substance use to neuropsycho-
logical test performance. Similar to the MACS group 
(3,27), we found no relationship. Still, this might re-
flect a limitation in our ability to reliably characterize 
drug use in ways that are most relevant to test perfor-
mance. Finally, we attempted to control for past sub-
stance abuse, and although we found that older pa-
tients with histories of long-term substance use were 
more likely to perform poorly on some tests, indepen-
dent effects of HIV status were still apparent. Our abil-
ity to prospectively relate changes in test performance 
to changes in disease severity suggests that we are truly 
assessing HIV-related changes and not simply 
changes due to drug use. 
We also noted a relationship between clinically sig-
nificant neurological changes and neuropsychological 
test performance. We have described a similar rela-
tionship in gay men (5). In cqmbination, our studies 
of gay men and !DU cohorts suggest that (a) HIV can 
affect cognition early, even when the patient is medi-
cally asymptomatic; (b) cognitive difficulties worsen 
as the severity of HIV infection increases; and ( c) the 
advent of clinically significant neuro!ogic signs is as-
sociated with progression to more severe cognitive 
deficits. Our data suggest that the neurological and 
neuropsychological changes are manifestations of the 
central effect of HIV on the CNS. 
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